PRTA
Prothena Corporation plc

2,006
Mkt Cap
$600.74M
Volume
79,010.00
52W High
$17.66
52W Low
$4.32
PE Ratio
-2.14
PRTA Fundamentals
Price
$11.11
Prev Close
$11.16
Open
$11.27
50D MA
$10.25
Beta
1.07
Avg. Volume
583,738.63
EPS (Annual)
-$2.27
P/B
2.04
Rev/Employee
$829,184.05
Loading...
Loading...
News
all
press releases
Prothena (NASDAQ:PRTA) Stock Price Up 7.4% - Here's Why
Prothena (NASDAQ:PRTA) Trading Up 7.4% - What's Next...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Citizens Jmp Forecasts Strong Price Appreciation for Prothena (NASDAQ:PRTA) Stock
Citizens Jmp upped their price target on Prothena from $11.00 to $19.00 and gave the company a "market outperform" rating in a report on Monday...
MarketBeat·3d ago
News Placeholder
Prothena Corporation plc (NASDAQ:PRTA) Given Average Recommendation of "Hold" by Brokerages
Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) has received a consensus rating of "Hold" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Two...
MarketBeat·12d ago
News Placeholder
Prothena Corporation plc $PRTA Position Lessened by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) by 79.3% in the second quarter, according to the company in its...
MarketBeat·13d ago
News Placeholder
Prothena Announces Poster Presentation on its TDP-43 CYTOPE Program at Neuroscience 2025
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a...
Business Wire·16d ago
News Placeholder
Quinn Opportunity Partners LLC Takes Position in Prothena Corporation plc $PRTA
Quinn Opportunity Partners LLC purchased a new position in shares of Prothena Corporation plc (NASDAQ:PRTA - Free Report) in the second quarter, according to its most recent disclosure with the...
MarketBeat·21d ago
News Placeholder
Cantor Fitzgerald Increases Earnings Estimates for Prothena
Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Stock analysts at Cantor Fitzgerald lifted their FY2026 earnings estimates for Prothena in a research report issued on Monday, November 10th...
MarketBeat·22d ago
News Placeholder
1,018,177 Shares in Prothena Corporation plc $PRTA Bought by Acadian Asset Management LLC
Acadian Asset Management LLC acquired a new position in Prothena Corporation plc (NASDAQ:PRTA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and...
MarketBeat·22d ago
News Placeholder
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the...
Business Wire·24d ago
News Placeholder
What is HC Wainwright's Estimate for Prothena Q2 Earnings?
Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Stock analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for shares of Prothena in a note issued to investors on...
MarketBeat·25d ago

Latest PRTA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.